Journal
Article title
Authors
Content
Title variants
Languages of publication
Abstracts
Gaucher disease (GD) is an autosomal recessive inborn error of metabolism, resulting from a deficiency of the enzyme glucocerebrosidase, causing an accumulation of the glycolipid glucocerebroside within lysosomes of macrophages in the reticuloendothelial system. Three major clinical forms have been assigned and more than 200 gene mutations have been identified. We herein report a Lebanese boy born with a novel combined mutation L371V/Rec-NciI, who presented with moderate-severe type 1 GD. An overview of the clinical and biomarker improvement following enzyme replacement therapy with imiglucerase is described in a follow-up of 30 months. Imiglucerase seems to be efficacious in decreasing the severity of the disease associated with this mutation. However, a high dose may be required to achieve optimal growth, platelet count, and hemoglobin level.
Keywords
Discipline
Journal
Year
Volume
Issue
Pages
421-424
Physical description
References
Document Type
ARTICLE
Publication order reference
Samar A. Muwakkit, Children?s Cancer Center, Department of Pediatrics, American University of Beirut Medical Center, P.O. Box: 11-0236, Riad El Solh 1107 2020, Beirut ? Lebanon
YADDA identifier
bwmeta1.element.element-from-psjc-f3359f1a-c75c-3d41-a6fc-16f9b085094a
Identifiers